Perihilar cholangiocarcinoma (pCCA) is a challenging disease with limited options. Surgical resection and adjuvant therapy remain the only established treatment for those with resectable disease. Since the publication of the Mayo protocol in 2000, neoadjuvant chemoradiation and liver transplantation have become the standard of care in selected patients with unresectable de novo pCCA or resectable pCCA arising under primary sclerosing cholangitis. However, its application is diverse worldwide, and the need for donor organs is one of the main limitations. Also, differences in the neoadjuvant regimen used were observed. In this review, we discuss the latest results of this approach, the recommended tools for diagnostic work-up, and advances in systemic therapy to improve patient selection and long-term survival.
Perihilar cholangiocarcinoma; Liver transplantation; Outcomes
Dopazo C, Charco R. Liver Transplantation for perihilar cholangiocarcinoma. Do we need to move forward? Hepatoma Res. 2023 Mar 29;9:10.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/10179
The following license files are associated with this item: